GHP Q4 2023 rapid solution to deliver fully human antibodies. OmniChicken was unveiled in 2016, the first engineered bird with an immune system that can efficiently create human sequence antibodies. Its evolutionary distance from humans and rodents enables the generation of diverse, affinity-matured antibodies against antigens that may be non-immunogenic in other mammals. Two antibodies – one derived from OmniMouse and one derived from OmniChicken – are in clinical development by OmniAb’s partners. Finally, OmniTaurTM, launched in 2020, provides cow-derived ultralong CDR-H3 antibodies that contain a human framework, enabling the discovery of antibody sequences that can access deep or cryptic epitopes due to their smaller size and unique domain features. OmniTaur seeks to provide a solution to an industry-wide problem: targeting ion channels, transporters, and viral protein epitopes, inaccessible to conventional antibodies. OmniAb offers the most diverse host systems available in the antibody discovery sector. Together, OmniAb’s four-species platform harnesses the power of each animal’s unique immune recognition capabilities to generate diverse antibody repertoires, allowing a multi-angled approach to antibody discovery for the benefit of its partners’ campaigns. Development of Bi- and Multi-specific Therapeutic Antibodies OmniAb has also generated animal hosts for binding dual or multiple therapeutic targets. Both OmniFlic® and OmniClic® are commonlight-chain rats and chickens, respectively, specifically designed to generate desirable candidates and facilitate development of bispecific antibodies. Three bispecific antibodies derived from OmniFlic are in clinical development. Recently, the company expanded its multi-specific antibody discovery platform, with the generation of Omni dAb™, the first and only transgenic chicken, capable of producing human singledomain antibodies. These antibodies have an array of benefits for therapeutic development, including leveraging modularly to efficiently design multi-specific antibodies for a wide range of human diseases. Coupled with the benefits of chicken-based antibody discovery, Omni dAb represents a powerful new tool for targeting distinct epitopes and accessing new treatment modalities. “There are a multitude of opportunities for single-domain antibodies due to the small and modular nature of the scaffold,” says Bill Harriman, Senior Vice President of Antibody Discovery at OmniAb, Inc. “And with the attributes that are built into our Omni dAb chicken platform, we are well positioned to accelerate the discovery of unique therapeutic molecules in this space.” Bill Harriman, PhD- Sr. Vice President, Antibody Discovery Kristen Chan- Antibody Discovery & Technology Sr. Research Associate
RkJQdWJsaXNoZXIy MTUyMDQwMA==